Financial Performance - For the year ended December 31, 2022, the revenue was RMB 2,339,650,000, an increase of approximately 14.4% compared to the year ended December 31, 2021[2] - The profit attributable to equity shareholders for the year ended December 31, 2022, was RMB 682,907,000, representing an increase of approximately 15.7% from the previous year[2] - Basic and diluted earnings per share for the year ended December 31, 2022, were approximately RMB 0.86, an increase of about 16.2% and 17.8% respectively compared to the previous year[2] - The gross profit for the year was RMB 1,762,912,000, compared to RMB 1,527,336,000 in the previous year[4] - Operating profit for the year was RMB 757,326,000, an increase from RMB 708,766,000 in the previous year[4] - Total comprehensive income for the year was RMB 683,928,000, compared to RMB 587,280,000 in the previous year[5] - The pre-tax profit for 2022 was RMB 746,393,000, an increase from RMB 695,861,000 in 2021, reflecting a growth of approximately 7.3%[30] - The actual tax expense for 2022 was RMB 62,696,000, down from RMB 108,744,000 in 2021, showing a decrease of about 42.4%[30] - The total dividend declared for the year was RMB 208,065,000, with a proposed final dividend of HKD 0.30 per share[35] Assets and Liabilities - Non-current assets as of December 31, 2022, totaled RMB 1,269,709,000, a slight decrease from RMB 1,306,909,000 in the previous year[6] - Current assets included cash and cash equivalents of RMB 2,450,173,000, an increase from RMB 2,196,323,000 in the previous year[6] - Total equity attributable to equity shareholders was RMB 3,145,139,000, up from RMB 2,617,705,000 in the previous year[7] - The total assets of the reporting segments increased to RMB 4,853,413,000 in 2022 from RMB 4,352,646,000 in 2021, reflecting a growth of 11.5%[16] - The total liabilities of the reporting segments decreased slightly to RMB 1,346,440,000 in 2022 from RMB 1,416,885,000 in 2021, a reduction of 4.9%[16] Revenue Breakdown - Revenue from customer contracts for 2022 reached RMB 2,339,650,000, an increase of 14.4% from RMB 2,044,660,000 in 2021[11] - The major product lines include nephrology drugs with revenue of RMB 1,569,418,000, up from RMB 1,364,683,000 in 2021, representing a growth of 15.0%[11] - The leading product, Uremic Granules, generated sales revenue of approximately RMB 1.50 billion, with a year-on-year growth of about 14.4%[63] - Sales revenue from the nephrology segment was approximately RMB 1.57 billion, reflecting a year-on-year growth of about 15.0%[63] - The sales revenue of medical imaging contrast agents was approximately RMB 160 million in 2022, with a year-on-year increase of 16.1%[64] - The sales revenue of women's and children's medications was around RMB 240 million in 2022, showing a year-on-year growth of 16.3%[64] - Yulin Pharmaceutical Division achieved sales revenue of approximately RMB 360 million, with a year-on-year growth of about 15.1%[64] Costs and Expenses - Employee costs for 2022 totaled RMB 445,669,000, up from RMB 365,996,000 in 2021, representing a year-over-year increase of approximately 21.8%[22] - Distribution costs increased by approximately 24.5% to RMB 771,960,000 in 2022, primarily due to increased marketing and academic promotion activities[85] - The administrative expenses increased by approximately 15.2% to RMB 322,504,000 in 2022, driven by higher R&D and labor costs[86] - Research and development costs for 2022 were RMB 117,539,000, compared to RMB 102,160,000 in 2021, indicating an increase of about 15.0%[24] - The total cost of inventory sold in 2022 was RMB 576,738,000, up from RMB 517,324,000 in 2021, indicating a year-over-year increase of 11.5%[47] Shareholder Information - The board proposed a final dividend of HKD 0.3 per share for the year ended December 31, 2022, subject to shareholder approval at the annual general meeting[115] - The proposed final dividend is subject to approval at the annual general meeting on May 31, 2023, and if approved, is expected to be paid around June 21, 2023[117] - The company repurchased 15,761,000 shares during the year, impacting the weighted average number of shares[32] - The company issued a total of 866,608 shares at a price between HKD 3.28 and HKD 4.01 due to employee stock options, with a total consideration of approximately HKD 3,171,000 (about RMB 2,638,000)[114] Market and Strategic Developments - The company plans to strengthen its position in the nephrology sector and expand its product lines, particularly in women's and children's health, while also enhancing its OTC offerings[80] - The company is collaborating with WuXi AppTec and Betta Pharmaceuticals on the development of innovative small molecule drugs for kidney disease and its complications, with three drugs currently in progress[70] - The company has completed registrations for several products in international markets, including Indonesia and the United States[65] - The company received TGA certification in Australia, allowing its products to be legally sold in the Australian market, which supports its international expansion strategy[79] - The company successfully renewed its products in the National Medical Insurance Catalog, including pain-relieving soft capsules and chicken bone grass capsules[65] Recognition and Awards - The company received the first prize in the 2022 China Integrative Medicine Science and Technology Award for its innovative diabetes kidney disease treatment strategy[67] - The company ranked 29th in the "Top 100 Chinese Traditional Medicine Enterprises" list, showcasing its strong brand influence and product performance[75] - The company's brand value reached 6.416 billion yuan, an increase of 1.432 billion yuan from 2021, reflecting its strong market presence[76] - The company was recognized in the "Top 50 Comprehensive Competitiveness of Traditional Chinese Medicine" list, reaffirming its leadership in the kidney disease market[77] - The company received the "2022 ESG Practice Model Award" for its outstanding contributions in the public welfare sector[78] Future Outlook - The company plans to optimize its business layout and enhance supply chain capabilities to ensure sustainable and stable growth in the future[81] - The average budgeted sales growth rate over a five-year period is projected at 11.6%, down from 14.3% in 2021[45] - The company expects to benefit from a reduced tax rate of 10% for small and micro enterprises in 2022, consistent with the previous year[28] - The company is actively responding to policy changes by optimizing its business structure, promoting transformation and upgrading, accelerating new product development, and managing costs effectively[105]
康臣药业(01681) - 2022 - 年度业绩